Preoperative bombesin administration can protect the rat small bowel allograft from ischemic reperfusion injury

J Pediatr Surg. 2005 Dec;40(12):1877-80. doi: 10.1016/j.jpedsurg.2005.08.035.

Abstract

Background/purpose: Ischemic reperfusion injury (IR/I) should be minimum for the success of small bowel transplantation (SBTx). This study investigated whether preoperative administration of neuropeptide bombesin (BBS) had a protective effect against IR/I and subsequent acute rejection.

Methods: Allogenic SBTx was performed heterotopically in rats (n = 18). All rats were administered FK506 (0.32 mg/kg per day) everyday. The rats were divided into 3 groups of 6 rats each: group 1, BBS(-)5: warm ischemic time (WIT), 5 minutes without BBS; group 2, BBS(-)15: WIT, 15 minutes without BBS; group 3, BBS(+)15: WIT, 15 minutes with BBS. The specimens were obtained from the stoma site at 1 hour after reperfusion and on postoperative day (POD) 1 and 7. The graft mucosal state and degree of acute rejection were evaluated by H&E staining. The apoptotic cells in the crypt lesion was evaluated using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling immunohistochemistry. Apoptotic index (AI) was calculated for quantitative analysis.

Results: H&E staining revealed that the mucosal villi on POD 1 remained shortened in the BBS(-)15 group than in the other two groups. One hour after reperfusion, the AI in the BBS(-)15 group was 145.0 per thousand +/- 37.2 per thousand, which was significantly higher (P < .05) than in the BBS(-)5 group (32.6 per thousand +/- 5.0 per thousand) or the BBS(+)15 group (32.0 per thousand +/- 3.0 per thousand). On POD 7, the AI in the BBS(-)15 group was 63.7 per thousand +/- 5.03 per thousand, which was significantly higher (P < .05) than in the BBS(-)5 (17.3 per thousand +/- 4.6 per thousand) or the BBS(+)15 group (12.3 per thousand +/- 3.06 per thousand).

Conclusions: Even a short WIT of 15 minutes induced considerable allograft mucosal damage, which also worsened acute rejection. Exogenous BBS could prevent mucosal damage by IR/I and was also beneficial for the prevention of acute rejection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Bombesin / pharmacology*
  • Graft Rejection / etiology
  • Graft Rejection / prevention & control*
  • Intestinal Mucosa / pathology
  • Intestine, Small / transplantation*
  • Male
  • Neurotransmitter Agents / pharmacology*
  • Preoperative Care
  • Rats
  • Reperfusion Injury / prevention & control*

Substances

  • Neurotransmitter Agents
  • Bombesin